3 active not recruiting, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Recurrent Cholangiocarcinoma: new trials by email Literature Review of Recurrent Cholangiocarcinoma trials Research Report on Recurrent Cholangiocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 2 | Active not recruiting | University of Kansas Medical Center | 15 | 2024-02-01 | 2026-02-24 |
| Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Glioblastoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 89 | 2019-01-30 | 2026-09-09 |
| Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Durvalumab, Guadecitabine - Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type | Phase 1 | Active not recruiting | University of Southern California | 55 | 2018-02-07 | 2026-06-01 |
| Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Non-Resectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma | Phase 1 | Withdrawn | Mayo Clinic | 2017-05-01 | 2017-05-30 |
Cholangiocarcinoma (4) · Klatskin Tumor (2) · Bile Duct Neoplasms (1) · Carcinoma, Hepatocellular (1) · Gallbladder Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Pancreatic Neoplasms (1)
Adenocarcinoma (4) · Carcinoma (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Biliary Tract Diseases (2) · Biliary Tract Neoplasms (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Neoplasms by Site (2) · Astrocytoma (1) · Bile Duct Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Gallbladder Diseases (1)
Biopsy (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Cisplatin (1) · Gemcitabine (1) · Platinum (1) · durvalumab (1) · guadecitabine (1) · olaparib (1) · ricolinostat (1) · sacituzumab govitecan (1)
Mayo Clinic (1) · National Cancer Institute (NCI) (1) · University of Kansas Medical Center (1) · University of Southern California (1)
United States (4)
Anthony El-Khoueiry, MD (1) · Kabir Mody (1) · Patricia M LoRusso (1)
P30CA014089 (1), P30CA015083 (1), P30CA168524 (1), UM1CA186689 (1)